BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accur...
325 Vassar Street
Cambridge, MA 02139
Founded in 2006
BIND Therapeutics, Inc. Announces Board Appointments
Sep 3 14
BIND Therapeutics, Inc. announced the appointments of Eric K. Rowinsky, M.D. and Amy W. Schulman to the company's board of directors. Eric K. Rowinsky, M.D., currently serves as Head of Research and Chief Medical Officer at Stemline Therapeutics and as a board member of Biogen Idec Inc. and was formerly Executive Vice President of Clinical Development and Regulatory at ImClone Systems. Amy W. Schulman is the Chief Executive Officer of Arsia Therapeutics and a Venture Partner at Polaris Partners. She is the former Executive Vice President and General Counsel of Pfizer Inc. and served as the Business Unit Lead for Pfizer's Consumer Healthcare business, after serving as President of the Nutrition Business.
BIND Therapeutics, Inc. Announces Presentation of Phase 2 Clinical Data on Bind-014 at 26th EORTC-NCI-AACR Symposium
Aug 26 14
BIND Therapeutics, Inc. announced that a poster presentation including Phase 2 clinical data on its lead drug candidate, BIND-014, in patients with non-small cell lung cancer (NSCLC) will be presented at the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. BIND-014 is a PSMA targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel in tumors which translated to marked improvements in antitumor activity. In a Phase 1 study, BIND-014 was well tolerated and showed initial indications of anti-tumor activity. BIND-014 is currently in two Phase 2 trials for the treatment of non-small cell lung cancer and metastatic castrate resistant prostate cancer.
BIND Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014
Aug 7 14
BIND Therapeutics, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $2,459,000, loss from operations of $8,216,000, net loss attributable to common stockholders of $8,444,000 or $0.51 per basic and diluted share compared to the revenue of $2,777,000, loss from operations of $5,632,000, net loss attributable to common stockholders of $7,331,000 or $3.32 per basic and diluted share for the same quarter a year ago.
For the six months period, the company reported revenue of $4,024,000, loss from operations of $16,735,000, net loss attributable to common stockholders of $16,766,000 or $1.02 per basic and diluted share compared to the revenue of $4,265,000, loss from operations of $11,768,000, net loss attributable to common stockholders of $14,957,000 or $6.83 per basic and diluted share for the same period a year ago.